In this issue:
Increased novel agent access in NZ improved MM survival
Impact of acquired del(17p) in MM
Pomalidomide-based regimens for relapsed/refractory MM
Daratumumab, lenalidomide + dexamethasone for untreated myeloma
Carfilzomib or bortezomib, + melphalan-prednisone, for transplant-ineligible new MM
Single-agent daratumumab in very advanced relapsed/refractory MM
Carfilzomib vs. bortezomib, + dexamethasone, in relapsed/ refractory MM
Impact of prior monoclonal gammopathy diagnosis on MM outcomes
Please login below to download this issue (PDF)